Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices Review Board: HRD-93-51
by U S Government Accountability Office (G
This GAO report (HRD-93-51) provides an in-depth analysis of Canada's Patented Medicine Prices Review Board, focusing on its role in regulating prescription drug prices. It explores the board's methods for ensuring fair pricing of patented medicines and offers insights into its effectiveness in the Canadian healthcare system.
About This Book
The U.S. Government Accountability Office (GAO) report titled 'Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices Review Board' examines the mechanisms used by the board to oversee pricing of patented medicines in Canada.
HRD-93-51 details the board's establishment, responsibilities, and processes for reviewing and adjusting drug prices to align with international standards and protect consumers.
The analysis highlights key findings on how the board influences prescription drug affordability and its impact on the pharmaceutical market.
This document serves as a resource for understanding comparative health policy approaches to drug pricing regulation.
Reviews
No reviews yet. Be the first to review this book!